Essex Bio-Technology is a biopharmaceutical company that develops, produces, and markets RB-bFGF (FGF-2) genetically engineered therapeutic products with six commercialized biologics that have been sold in China since 1998.
The Company’s drugs are mainly prescribed in Ophthalmology & Dermatology for the treatment of wound healing and diseases, which are marketed and distributed by approximately 8,880 hospitals and directly operated by its 43 regional sales offices in China.
Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
This Hong-Kong based VC appers to be open.
Hong Kong, Hong Kong/ China, SAR